Cryopyrin-associated Periodic Syndrome
📧 Sign up to get email alerts when something new happens for Cryopyrin-associated Periodic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) [Phase 1]
A Phase 1 study evaluating the safety, tolerability, efficacy, and pharmacokinetics of JTE-162 in subjects with cryopyrin-associated periodi…
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome [Phase 2]
This update reports the completion of a Phase 2 trial evaluating VTX2735 in patients with Cryopyrin-associated periodic syndrome.
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) [Phase 2]
Phase 2 trial for ATI-450 in Cryopyrin-Associated Periodic Syndrome was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2022-07-11Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS) [Phase 2]
Phase 2 clinical trial evaluating safety, tolerability, PK and PD of ZYIL1 in subjects with Cryopyrin Associated Periodic Syndromes (CAPS) h…
-
CLINICAL_TRIALS trial_result · 2017-03-21Clinical Trial Update: The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada [Phase 3]
Phase 3 trial evaluating the safety and efficacy of canakinumab in patients aged 4 years or older with Cryopyrin-associated periodic syndrom…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2009-02-17Clinical Trial Update: Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms [Phase 2]
Phase 2 trial update evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of ACZ885 (canakinumab) in patients with NLRP3 mutat…